Schoels W, Yang H, Gough W B, el-Sherif N
Department of Medicine, State University of New York Health Science Center, Brooklyn.
Circ Res. 1991 Apr;68(4):1117-26. doi: 10.1161/01.res.68.4.1117.
To evaluate the mechanisms of action of procainamide on the components of the reentrant pathway, drug-induced changes in activation patterns, effective refractory periods (ERPs), and stimulation thresholds were analyzed in nine dogs with sterile pericarditis and sustained atrial flutter. Activation maps were based on 127 close bipolar recordings from a special "jacket" electrode. From the control map, 22 +/- 2 sites covering the slow zone and the normal zone of the reentrant circuit were selected to measure ERPs and thresholds. The excitable gap was estimated from the longest ERP during pacing at the tachycardia cycle length. During atrial flutter, epicardial activation proceeded as a single wave around an arc of functional conduction block in the proximity of the atrioventricular (AV) ring or around a combined functional/anatomic obstacle, with the arc being contiguous with one of the venae cavae. An area of slow conduction, which accounted for 53 +/- 15% of the revolution time within 35 +/- 15% of the total length of the reentrant pathway, was bordered by the arc of block and the AV ring or a caval vein and the AV ring, respectively. Procainamide (5-10 mg/kg i.v.) prolonged the cycle length of atrial flutter from 144 +/- 17 to 190 +/- 24 msec (p less than 0.05) and then terminated the arrhythmia in all studies. The increase in cycle length was due to an increase in conduction time in the slow zone by 37 +/- 11 msec (86 +/- 17% of the total cycle length increase). During the last reentrant beat, conduction failed in the slow zone, with the arc of block joining the AV ring. At termination, procainamide had prolonged conduction time, stimulation threshold, and ERP in the normal zone by 11 +/- 18%, 40 +/- 80%, and 5 +/- 15%, respectively, compared with 51 +/- 16%, 86 +/- 93%, and 14 +/- 21%, respectively, in the slow zone (p less than 0.05 for all three parameters). The duration of the excitable gap did not change significantly. We conclude that procainamide preferentially affected the slow zone of single loop reentrant circuits. The drug terminated circus movement atrial flutter without abolishing the excitable gap, and its effect on conduction seemed the major determinant of the antiarrhythmic action.
为评估普鲁卡因胺对折返径路各组成部分的作用机制,分析了9只患有无菌性心包炎和持续性心房扑动犬的药物诱导的激活模式、有效不应期(ERP)及刺激阈值变化。激活图基于来自特殊“套状”电极的127个紧密双极记录。从对照图中,选择覆盖折返环慢区和正常区的22±2个部位来测量ERP和阈值。根据心动过速周期长度起搏时最长的ERP估算可兴奋间隙。心房扑动时,心外膜激活以单个波的形式围绕房室(AV)环附近的功能性传导阻滞弧或围绕功能性/解剖性联合障碍物进行,该弧与其中一条腔静脉相邻。一个缓慢传导区域,占折返径路总长度35±15%内折返时间的53±15%,分别由阻滞弧与AV环或腔静脉与AV环界定。静脉注射普鲁卡因胺(5 - 10mg/kg)使心房扑动的周期长度从144±17毫秒延长至190±24毫秒(p<0.05),然后在所有研究中终止心律失常。周期长度增加是由于慢区传导时间增加37±11毫秒(占总周期长度增加的86±17%)。在最后一次折返搏动期间,慢区传导失败,阻滞弧与AV环相连。在心律失常终止时与慢区相比,普鲁卡因胺使正常区的传导时间、刺激阈值和ERP分别延长了11±18%、40±80%和5±15%,而慢区分别为51±16%、86±93%和14±21%(所有三个参数p<0.05)。可兴奋间隙的持续时间无显著变化。我们得出结论,普鲁卡因胺优先影响单环折返电路的慢区。该药物终止了环形运动性心房扑动而未消除可兴奋间隙,其对传导作用似乎是抗心律失常作用的主要决定因素。